Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic DermatitisBusiness Wire • 04/07/21
Pfizer's CEO Makes a Claim That Might Shock Anyone Holding Moderna or BioNTech StockThe Motley Fool • 04/06/21
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021Business Wire • 04/02/21
Pfizer and BioNTech's Coronavirus Vaccine Remains Effective for at Least 6 MonthsThe Motley Fool • 04/01/21